Stefanie Perrella

Stefanie Perrella

Managing Director

Stefanie Perrella is a managing director and the Global Head of Transfer Pricing, based in the New York office. Stefanie has been providing strategic advice on complex pricing and valuation questions for her clients for more than a decade.

Prior to serving as Global Head of Transfer Pricing, Stefanie led the New York Transfer Pricing practice and was the co-leader of the global Financial Transactions Transfer Pricing team. Before joining the firm, Stefanie served as an associate director for Ceteris, which was acquired by Kroll in 2012. She began her career in transfer pricing at NERA Economic Consulting.

Stefanie has experience assisting a range of clients with all aspects of global transfer pricing, including planning, compliance, implementation and disputes. She is a thought leader on transfer pricing for financial services clients as well as establishing best practices for assessing intercompany debt and other financing arrangements for the firm’s top clients across a wide spectrum of industries. She also has significant experience with intangible transfers and has co-led numerous disputes around these valuation issues, primarily in the pharmaceutical and medical device space.

Stefanie received a B.S. (summa cum laude) in international affairs with a concentration in finance and an M.A. in international economic relations from American University. She has authored numerous publications and is an award-winning speaker who has presented on a range of valuation and pricing topics at international conferences and at universities.



Valuation

Valuation of businesses, assets and alternative investments for financial reporting, tax and other purposes.

Transfer Pricing

Kroll's team of internationally recognized transfer pricing advisors provide the technical expertise and industry experience necessary to ensure understandable, implementable and supportable results.

Full Value of Vaccine Assessment of Microarray Patches (FVVA) for Typhoid Conjugate Vaccines

Full Value of Vaccine Assessment of Microarray Patches (FVVA) for Typhoid Conjugate Vaccines

This report was written by Gavi, drawing on extensive analysis undertaken by the Swiss Tropical and Public Health Institute, MMGH Consulting, Kroll and BDO. Additional analyses supported by Vaccine Innovation Prioritisation Strategy (VIPS) Alliance members WHO, UNICEF, Gavi, PATH, and the Bill and Melinda Gates Foundation.

 

Learn More